Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.54 |
| ▸ | IDO1 | P14902 | 2/20 | 0.52 |
| ▸ | ACHE | P22303 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | CTBP2 | P56545 | 1/20 | 0.42 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL177507 | 0.98 | — | — | |
| SCHEMBL30589449 | 0.98 | — | — | |
| SCHEMBL7274625 | 0.95 | TAAR1 (0.54) | TAAR1IDO1ACHEALDH1A1MAPK1 | |
| Methoxymethane SCHEMBL27460723 | 0.91 | IDO1 (0.53) | TAAR1IDO1ACHEALDH1A1MAPK1 | |
| Trimethylammonium SCHEMBL6257520 | 0.91 | TAAR1 (0.50) | TAAR1IDO1ACHEALDH1A1MAPK1 | |
| SCHEMBL10879486 | 0.89 | TAAR1 (0.48) | TAAR1IDO1ACHEALDH1A1MAPK1 | |
| SCHEMBL2935079 | 0.85 | CYP4F2 (0.46) | TAAR1IDO1ACHEALDH1A1MAPK1 | |
| SCHEMBL2646995 | 0.82 | ALDH1A1 (0.45) | TAAR1IDO1ACHEALDH1A1TRPA1 | |
| SCHEMBL20398408 | 0.82 | — | — | |
| SCHEMBL10877262 | 0.80 | ALDH1A1 (0.53) | IDO1ACHEALDH1A1TSHRMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8859546-B2 | Picolinamide inhibitors of kinases | ABBVIE INC. (US) | 2014-10-14 | — | — | US | disclosed |
| EP-2665711-A1 | PICOLINAMIDE INHIBITORS OF KINASES | Abbvie Inc. (US) | 2013-11-27 | — | — | EP | disclosed |
| WO-2012100135-A1 | PICOLINAMIDE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | WO | disclosed |
| US-20120190681-A1 | PICOLINAMIDE INHIBITORS OF KINASES | ABBOTT LABORATORIES (US) | 2012-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120190681-A1 | PICOLINAMIDE INHIBITORS OF KINASES | ALK, PKN2, ERBB2 | TAAR1 1281/4885IDO1 2470/4885ACHE 3877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.